EMPE DIAGNOSTICS - MAKING RELIABLE INFORMATION IN THE FIRST CLINICAL MEETING POSSIBLE
MULTIPLEX LATERAL FLOW SIMPLICITY
We offer indigienous, customized, and ready-to-use molecular test kits for the identification of drug-resistance or drug-susceptibility. Our multiplex nucleic acid tests provide YES/NO answers in 70 min by developing a visual signal. Though the versatility of our technology allows high-throughput detection, we are currently focusing on tuberculosis and sexually transmitted infections.
STATE OF THE ART DNA TECHNOLOGY
For the first time in the diagnostic industry, EMPE Diagnostics has combined the highly stringent padlock probe-dependent rolling circle amplification technique with sensitive lateral flow biosensors, enabling pragmatic multiplex detection of infectious microbes.
The precision of single-molecule detection capacity offers reliable detection of different bacteria, virus, fungi, and other microbes, in a single test (including their wild types and mutations). Our patented technology offers confirmatory detection of nucleic acids (DNA/RNA) providing highly sensitive visual signals even in resource-limited clinical laboratories across the world.
No Electricity - No Refrigeration - No Special Instruments
Multiplex detection in 70 minutes.
WHO (World Health Organisation) has stated that Tuberculosis (TB) is one of the major infectious diseases across the world, and the 10th major cause of deaths. About 1.7 billion people are at risk of developing TB and about 10.4 million people are newly getting infected every year. More than 4500 people die every day because of TB infections, and the rate of infections increases sharply if TB is associated with immunosuppressive conditions like HIV and/or other sexually transmitted diseases. The TB bacteria can develop multi/extensive drug resistance (MDR/XDR), which requires up to USD 50,000 to treat one patient. Many patients have to take 2-8 pills and injections every day for up to 36 months, or the rest of their lives.
Globally, TB-treatment costs more than $10 billion/year, but 20-50% of the patients receive incorrect antibiotics because the current diagnostic methods require expensive instruments, infrastructure and skilled personnel. Management of TB is a significant health care burden for the country. Therefore, a suitable solution is needed for more than 200 countries among Asia, Africa, and some countries in Europe and the Americas.
WHO concludes that the development of easy-to-use point-of-care diagnostics is the key in TB management. By following WHO guidelines, EMPE Diagnostics has intelligently developed a rapid and multiplex diagnostic platform.
DETECTION OF MULTI/EXTENSIVELY DRUG RESISTANT TB (MDR/XDR-TB)
Several millions of people are infected with TB, spreading the disease via their cough, across the world. The bacteria, Mycobacterium tuberculosis, causing TB can reside in the body for years without initiating any symptom (latent TB), and could spread to other parts of the body.
Correct detection of TB bacterial genotypes coding for resistance takes up to 6 months because the bacteria takes months to grow. At present, the proper detection of resistant TB-genotypes is a long process that takes up to 6 months in developing countries. Clinicians are forced to consider microscopy results due to the non-availability of point-of-care confirmatory diagnostics at sputum microscopy centers. Therefore, based on the microscopic results the doctors start empirical antibiotic therapy after the first diagnosis.
Failure in correct identification leads to the development of MDR/XDR-TB, where sophisticated molecular tests costs about $100-$500 per patient, and the treatment costs $20 000-$50 000 per patient. WHO estimates that about 75% of all MDR-TB cases are not identified and reported. By bringing down the diagnosis time it is possible to restrict the spread of multi-drug resistance in tuberculosis.